CeleScreen
- BETA
To investigate (B)
Some signals may appear as inconsistent with a regular activity Social networks
118 302Activities
Technologies
Entity types
Location
2 Rue Ambroise Paré, 75010 Paris, France
Paris
France
Employees
Scale: 1 employee
Estimated: 2
SIREN
811862978Engaged corporates
8
3 5Added in Motherbase
2 years, 6 months ago
cosmetics Value proposition
CeleScreen develops an innovative technology for the rapid screening of xenobiotics toxicity by means of Caenorhabditis elegans, a <1mm nematode, long-known model for human metabolism. It is a unique solution for systemic toxicity, reprotoxicity, teratogenicity, while avoiding vertebrate testing. Primary targets are in the cosmetics industry to face REACH demands. Celescreen has recently launched collaborative projects incorporating C. elegans and in silico approaches for drug development in human health.
Incorporated in 2015, based at Hôpital Lariboisière in Paris, CeleScreen is a licensee of Assistance Publique - Hôpitaux de Paris (AP-HP), a major player in human health with >20,000 medical doctors.
toxicology, systemic toxicity, reprotoxicity, teratogenicity, REACH, drug design, lead optimization, and C. elegansOriginal language
CeleScreen develops an innovative technology for the rapid screening of xenobiotics toxicity by means of Caenorhabditis elegans, a <1mm nematode, long-known model for human metabolism. It is a unique solution for systemic toxicity, reprotoxicity, teratogenicity, while avoiding vertebrate testing. Primary targets are in the cosmetics industry to face REACH demands. Celescreen has recently launched collaborative projects incorporating C. elegans and in silico approaches for drug development in human health.
Incorporated in 2015, based at Hôpital Lariboisière in Paris, CeleScreen is a licensee of Assistance Publique - Hôpitaux de Paris (AP-HP), a major player in human health with >20,000 medical doctors.
CeleScreen - Innovative method of assessing toxicity in systemic organism
Celescreen develops an innovative process of assessing toxicity in systemic organism using an invertebrate, the worm Caenorhabditis elegans
http://www.celescreen.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 3 Dec 2015 | | |
 50 Partners Startup accelerator & VC, Venture Capital & Private Equity | 50 Partners Startup accelerator & VC, Venture Capital & Private Equity | Other 20 May 2015 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Not capitalistic Not partnership Event 7 Jul 2016 | | |
 Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Other 28 Sep 2015 | | |
 Agoranov Startup accelerator & VC, Technology, Information and Internet | Agoranov Startup accelerator & VC, Technology, Information and Internet | Not capitalistic Partnership Event 7 Jul 2016 | | |
 Paris&Co Startup accelerator & VC, Civic and Social Organizations | Paris&Co Startup accelerator & VC, Civic and Social Organizations | Not capitalistic Not partnership Event 3 Dec 2015 | | |
 L'Express Media, Newspaper Publishing | L'Express Media, Newspaper Publishing | Not capitalistic Not partnership Event 30 Nov 2015 | | |
 HEC Paris Higher Education | HEC Paris Higher Education | Not capitalistic Not partnership Event 25 Jan 2016 | | |